# Multiplex imaging and analysis using the Enable Cloud Platform to predict TNF inhibitor response in ulcerative colitis patients

## Case study

**April 1, 2023**

Ulcerative colitis (UC) is a chronic-relapsing inflammatory bowel disease (IBD). Patients with UC have a 1.5 times higher risk for colorectal cancer compared to healthy individuals. TNF inhibitors such as infliximab and adalimumab are frontline targeted therapies for UC but 13-40% UC patients are non-responsive to TNFi therapy and up to 46% show loss of resistance. Since these drugs are immunosuppressive, they can lead to opportunistic infections, driving up the cost following UC treatment, especially in non-responders. In order to implement individualized therapy to patients effectively, it is critical to understand the differences between individual patients that could affect responses to TNF therapy.

.svg)

## Download Resource

Thank you! Your resource is now ready. Click the button below to download.

[Download the PDF](https://cdn.prod.website-files.com/65ca6abb275ffa2a6cd94f2e/6601d84e3ca83f8f33f6e62c_Enable%20Medicine%20Ulcerative%20Colitis%20Tech%20Note%20(2)-min.pdf)

### Related Links
- [Autoimmune](https://www.enablemedicine.com/use-case/autoimmune)
- [Biomarkers](https://www.enablemedicine.com/use-case/biomarkers)
- [Patient stratification](https://www.enablemedicine.com/use-case/patient-stratification)
- [Cell microenvironment](https://www.enablemedicine.com/use-case/cell-microenvironment)
- [Patient response](https://www.enablemedicine.com/use-case/patient-response)
- [Ulcerative Colitis](https://www.enablemedicine.com/use-case/ulcerative-colitis)